JP2023502929A - Ｈｅｒ２陽性乳がんを抗ｈｅｒ２抗体－薬物コンジュゲートと併用してツカチニブで治療する方法 - Google Patents

Ｈｅｒ２陽性乳がんを抗ｈｅｒ２抗体－薬物コンジュゲートと併用してツカチニブで治療する方法 Download PDF

Info

Publication number
JP2023502929A
JP2023502929A JP2022527994A JP2022527994A JP2023502929A JP 2023502929 A JP2023502929 A JP 2023502929A JP 2022527994 A JP2022527994 A JP 2022527994A JP 2022527994 A JP2022527994 A JP 2022527994A JP 2023502929 A JP2023502929 A JP 2023502929A
Authority
JP
Japan
Prior art keywords
subject
tucatinib
her2
drug conjugate
her2 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022527994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502929A5 (https=
JPWO2021097220A5 (https=
Inventor
ルーク ウォーカー，
ジョージ ラモス，
オールマ パーカー，
アニタ クルキアン，
Original Assignee
シージェン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シージェン インコーポレイテッド filed Critical シージェン インコーポレイテッド
Publication of JP2023502929A publication Critical patent/JP2023502929A/ja
Publication of JP2023502929A5 publication Critical patent/JP2023502929A5/ja
Publication of JPWO2021097220A5 publication Critical patent/JPWO2021097220A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022527994A 2019-11-15 2020-11-13 Ｈｅｒ２陽性乳がんを抗ｈｅｒ２抗体－薬物コンジュゲートと併用してツカチニブで治療する方法 Pending JP2023502929A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962935989P 2019-11-15 2019-11-15
US62/935,989 2019-11-15
US201962945321P 2019-12-09 2019-12-09
US62/945,321 2019-12-09
US202063071800P 2020-08-28 2020-08-28
US63/071,800 2020-08-28
PCT/US2020/060431 WO2021097220A1 (en) 2019-11-15 2020-11-13 Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate

Publications (3)

Publication Number Publication Date
JP2023502929A true JP2023502929A (ja) 2023-01-26
JP2023502929A5 JP2023502929A5 (https=) 2023-11-13
JPWO2021097220A5 JPWO2021097220A5 (https=) 2023-11-13

Family

ID=73740595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022527994A Pending JP2023502929A (ja) 2019-11-15 2020-11-13 Ｈｅｒ２陽性乳がんを抗ｈｅｒ２抗体－薬物コンジュゲートと併用してツカチニブで治療する方法

Country Status (10)

Country Link
US (1) US20220387618A1 (https=)
EP (1) EP4058024A1 (https=)
JP (1) JP2023502929A (https=)
KR (1) KR20220115566A (https=)
CN (1) CN114945369A (https=)
AU (1) AU2020381495A1 (https=)
CA (1) CA3159770A1 (https=)
IL (1) IL292886A (https=)
MX (1) MX2022005903A (https=)
WO (1) WO2021097220A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060407A1 (en) 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers
MX2022004699A (es) * 2019-10-21 2022-08-08 Seagen Inc Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab.
US12133966B2 (en) 2020-12-22 2024-11-05 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
WO2023220336A1 (en) * 2022-05-13 2023-11-16 Herzlinger Regina E Methods, systems, and apparatus for administering an antibody treatment via infusion
WO2023061472A1 (zh) * 2021-10-14 2023-04-20 江苏恒瑞医药股份有限公司 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
MX2024010916A (es) * 2022-03-07 2024-09-17 Mersana Therapeutics Inc Conjugados anticuerpo-farmaco que comprenden agonistas de sting, combinaciones y metodos de uso.
KR20250089514A (ko) * 2022-10-18 2025-06-18 자임워크스 비씨 인코포레이티드 글리피칸-3을 표적화하는 항체-약물 접합체 및 사용 방법
TW202502352A (zh) 2023-03-10 2025-01-16 美商思進公司 使用抗ｈｅｒ２抗體－藥物結合物及ｈｅｒ２激酶抑制劑治療癌症之方法
WO2025049926A1 (en) * 2023-08-31 2025-03-06 Yale University Methods of selecting treatment options for cancer
WO2025054916A1 (en) * 2023-09-14 2025-03-20 Remegen Co., Ltd. Methods of treating cervical cancer using anti-her2 antibody-drug conjugates
KR20250043317A (ko) * 2023-09-21 2025-03-28 주식회사 피노바이오 운반체-약물 접합체 및 dnmt-1 저해제의 병용 요법
TW202541808A (zh) 2023-12-20 2025-11-01 德商百靈佳殷格翰國際股份有限公司 抗癌組合治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201016A1 (en) * 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633410A (en) 1898-09-22 1899-09-19 George A Ames Ice-cutter.
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
JP2006500364A (ja) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
KR20140032004A (ko) 2004-07-22 2014-03-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
NZ602675A (en) 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
CN107325182A (zh) 2008-04-02 2017-11-07 宏观基因有限公司 HER2/neu‑特异性抗体和其使用方法
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
BR122020010643B1 (pt) 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
RU2629116C2 (ru) 2011-10-14 2017-08-24 Эррэй Биофарма Инк. Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
WO2013055874A2 (en) * 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
MX379256B (es) 2013-03-15 2025-03-10 Regeneron Pharma Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
WO2014200891A1 (en) 2013-06-11 2014-12-18 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES Her2-specific monoclonal antibodies and conjugates thereof
KR102252925B1 (ko) 2013-08-26 2021-05-18 리제너론 파마슈티칼스 인코포레이티드 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
KR101993136B1 (ko) 2013-11-19 2019-06-26 레메젠 리미티드 항-her2 항체 및 이의 접합체
KR20170042495A (ko) 2013-12-16 2017-04-19 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
HUE029672T2 (en) 2014-01-10 2017-03-28 Synthon Biopharmaceuticals Bv Duokarmicin-ADCs for use in the treatment of endometrial cancer
SI3466976T1 (sl) 2014-01-31 2021-12-31 Daiichi Sankyo Company, Limited Anti-her2 konjugat protitelesa-zdravila
MX2016012830A (es) 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
LT3191135T (lt) 2014-09-12 2020-11-25 Genentech, Inc. Anti-her2 antikūnai ir imunokonjugatai
EA034950B1 (ru) 2015-03-27 2020-04-09 Регенерон Фармасьютикалз, Инк. Производные майтанзиноида, их конъюгаты и способы использования
WO2017132173A1 (en) 2016-01-25 2017-08-03 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
SG10201912173RA (en) 2016-10-07 2020-02-27 Daiichi Sankyo Co Ltd Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
MX2020011487A (es) 2018-04-30 2020-12-07 Regeneron Pharma Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201016A1 (en) * 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMA ONCOL., vol. 4, no. 9, JPN6024045103, 2018, pages 29955792, ISSN: 0005587121 *

Also Published As

Publication number Publication date
MX2022005903A (es) 2022-12-13
CN114945369A (zh) 2022-08-26
IL292886A (en) 2022-07-01
KR20220115566A (ko) 2022-08-17
CA3159770A1 (en) 2021-05-20
WO2021097220A1 (en) 2021-05-20
EP4058024A1 (en) 2022-09-21
AU2020381495A1 (en) 2022-05-19
US20220387618A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
JP2023502929A (ja) Ｈｅｒ２陽性乳がんを抗ｈｅｒ２抗体－薬物コンジュゲートと併用してツカチニブで治療する方法
AU2022241509B2 (en) Treatment of HER2 positive cancers
WO2021190637A1 (en) Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
US20230270745A1 (en) Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
JP2023527794A (ja) トラスツズマブ及びオキサリプラチン系化学療法と組み合わせたツカチニブによるｈｅｒ２陽性癌を治療する方法
KR20230005269A (ko) 암 치료를 위한 투여 요법
KR20200061382A (ko) 암을 치료하기 위한 조성물 및 방법
CA3135165A1 (en) Methods of treating cancer with chk1 inhibitors
AU2023372369B2 (en) Combination therapy for treating cancer
JP2022532597A (ja) Ｃｈｋ１阻害剤を使用してがんを治療する方法
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
WO2024263643A1 (en) Compositions comprising antineoplastons and methods of treating breast cancer
HK40070611A (en) Combination of anti-her2 antibody and cdk inhibitor for tumor treatment
HK40076724A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241107

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250110

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250507